UPDATE: We are proud to announce, along with @BioNTech_Group, that our mRNA-based #vaccine candidate has, at an interim analysis, demonstrated initial evidence of efficacy against #COVID19 in participants without prior evidence of SARS-CoV-2 infection.
Pfizer Inc.
11.4K posts
We’re celebrating over 175 years of daring scientific innovation and we’re not done yet. Protect your health at PfizerForAll.com on.pfizer.com/CGs
- Today, we were joined by Rwanda, Ghana, Senegal, Malawi & Uganda as we launched a new initiative to help close the global health equity gap & enable sustained access to medicines and vaccines in 45 lower-income countries. More here: on.pfizer.com/3afNuKx #HealthEquity #WEF22
00:00 - BREAKING: We are proud to announce, along with @BioNTech_Group, that the Phase 3 study of our #COVID19 vaccine candidate has met all primary efficacy endpoints.
- Today we have announced we are mobilizing the largest humanitarian relief effort in our company’s history to help the people of India fight the vicious second wave of coronavirus that is currently ravaging the nation.
00:00 - We now have more than 25,000 participants dosed in our #COVID19 vaccine clinical trial. Learn more about our progress in developing a potential #COVID19 vaccine, here: on.pfizer.com/3jOCfbn
- Today, with @BioNTech_Group, we announced positive topline results in adolescents 12-15 years of age from the Phase 3 Pfizer-BioNTech #COVID19 vaccine study.
- BREAKING: Today, with @BioNTech_Group, we initiated the submission of a BLA for @FDA approval of the Pfizer-BioNTech #COVID19 vaccine to prevent COVID-19 in individuals 16 years and older.
- UPDATE: We and @BioNTech_Group officially submitted our request to @US_FDA for Emergency Use Authorization (EUA) of our #COVID19 vaccine in children 5 to <12.
00:00 - BREAKING: Today, with @BioNTech_Group, we submitted a request to US FDA to expand emergency use of our COVID-19 vaccine to adolescents 12 to 15 years of age.
- Replying to @pfizerWe are donating enough of these medicines to ensure that every COVID-19 patient in every public hospital across India can have access to them in the next 90 days free of charge. This effort has the potential to impact the lives of hundreds of thousands of patients.
- Replying to @pfizerEfficacy in the majority of participants, safety data and consistent manufacturing are the three requirements that are needed before we are able to file for Emergency Use Authorization.





